Drugs / Levodopa-carbidopa intestinal gel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00360568 | Jun 2009 → Oct 2012 | Parkinson disease, movement disorder | AbbVie | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-29 | AbbVie | Results AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting abbvie.com ↗
Long-term Motor and Non-Motor Symptom Benefits in Patients with Advanced Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel: Final Analysis of the 36-Month DUOGLOBE Real-world Multinational Observational Study |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-29 | AbbVie | AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting abbvie.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levodopa-carbidopa intestinal gel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00360568 ↗ |
| Known as | LCIG | “Study S187.3.003 (NCT00360568) is a Phase 3, 12-month, open-label, multicenter continuation treatment study of the safety, tolerability, and efficacy of levodopa-carbidopa...” NCT00360568 ↗ |